According to the latest filing submitted to the U.S. Securities and Exchange Commission, healthcare giant Concentrix has explicitly stated its plan to reaffirm its 2026 financial targets.

The company expects that by then, its diluted earnings per share calculated under GAAP will exceed $1.98, while adjusted earnings per share are targeting the important threshold of over $3.00. The confirmation of this guidance highlights management's strong confidence in the company's medium- and long-term profitability. Despite policy changes and cost pressures in the healthcare industry, Conxico has demonstrated strong resilience in continuously creating shareholder value through refined operations and strategic planning. Notably, the establishment of dual earnings per share metrics provides investors with a more comprehensive performance evaluation dimension, encompassing both standard financial performance and core operating results after excluding special items. As the 2026 milestone approaches, the market will closely watch how the company achieves these ambitious goals through business optimization and technological innovation. The reiteration of this guidance not only consolidates capital market expectations for the company, but also conveys management's precise control over the future growth trajectory.